Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-25T19:27:34.443Z Has data issue: false hasContentIssue false
  • English
  • Français

Somatostatin receptor imaging of olfactory neuroblastoma

Published online by Cambridge University Press:  29 June 2007

Hans A. Ramsay ,
Kalevi J. A. Kairemo  and
Antti P. Jekunen
Hans A. Ramsay*
Affiliation:
Departments of Otolaryngology, University Hospital of Helsinki, Finland.
Kalevi J. A. Kairemo
Affiliation:
Department of Oncologyt, University Hospital of Helsinki, Finland.
Antti P. Jekunen
Affiliation:
Department of Oncologyt, University Hospital of Helsinki, Finland.
*
Address for correspondence: Hans A. Ramsay, M.D., ENT department, University Hospital, Haartmansstreet 4E, FIN-00290 Helsinki, Finland. Fax: +358-9-4715010.
Get access Rights & Permissions [Opens in a new window]

Abstract

Neural-crest tumours, including neuroblastomas, express somatostatin receptors. This can be shown by radionuclide labelling of octreotide, a somatostatin analogue. Studies on imaging with this substance have dealt with childhood neuroblastomas. Olfactory neuroblastoma (aesthesioneuroblastoma) is a rare tumour in which somatostatin receptor content has not been analysed, nor have radionuclide methods for diagnostic purposes been described. We report a case of olfactory neuroblastoma, in which scanning with m In-labelled octreotide was performed. A strong uptake was seen at the base of the skull. This was confirmed as a recurrent tumour by magnetic resonance (MR) imaging. Uptake was also observed in the neck and chest, indicating extensive spread of the disease.

Somatostatin receptor expression has been shown to correlate with prognosis in childhood neuroblastoma. The accuracy of labelled octreotide in the diagnosis of olfactory neuroblastoma indicates that it might be useful in radionuclide therapy of patients with advanced disease, when no other treatment modalities are available.

Keywords

SomatostatinOctreotideNeuroblastoma, olfactory
Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 110 , Issue 12 , December 1996 , pp. 1161 - 1163
Copyright
Copyright © JLO (1984) Limited 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bethge, N., Diel, F., Rösick, M., Holz, J. (1981) Somatostatin half-life: A case report in one healthy volunteer and a three month follow-up. Hormone and Metabolic Research 13: 709–710.CrossRefGoogle Scholar
Biersack, H. J., Briele, B., Hotze, A. L., Oehr, P., Qian, L., Mekkawy, M. A., Shih, W. J. (1992) The role of nuclear medicine in oncology. Annals of Nuclear Medicine 6: 131–136.CrossRefGoogle ScholarPubMed
Gottesman, I. S., Mandarino, L. J., Gerich, J. E. (1982) Somatostatin: Its role in health and disease. In. Special Topics in Endocrinology and Metabolism (Cohen, M. and Foa, P., eds.) Vol. 4. Alan R. Liss, New York, pp 177–243.Google Scholar
Kairemo, K. J. A., Jekunen, A. P., Ramsay, H. A., Jääskelä-Saari, H. A. (1995) Use of bleomycin in radiochemotherapy. Journal of Nuclear Medicine 36: 1531.Google ScholarPubMed
Kairemo, K. J. A., Ramsay, H. A., Tagesson, M., Jekunen, A. P., Paavonen, T. K., Jääskelä-Saari, H. A., Liewendahl, K., Ljunggren, K., Savolainen, S., Strand, S.-E. (1996) 111Indium-bleomycin complex for radiochemotherapy of head and neck cancer—dosimetric and biokinetic aspects. European Journal of Nuclear Medicine 20: 631–638.CrossRefGoogle Scholar
Krenning, E. P., Bakker, W. H., Breeman, W. A. P., Koper, J. W., Kooij, P. P., Ausema, L., Lameris, J. S., Reubi, J. C., Lamberts, S. W. (1989) Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1: 242–244.CrossRefGoogle ScholarPubMed
Kvols, L. K., Moertel, C. G., O'Conell, M. J., Schutt, A. J., Rubin, J., Hahn, R. G. (1986) Treatment of malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. New England Journal of Medicine 315: 663–666.CrossRefGoogle ScholarPubMed
Lund, V. J., Milroy, C. (1993) Olfactory neuroblastoma: Clinical and pathological aspects. Rhinology 31: 1–6.Google ScholarPubMed
Manil, L., Perdereau, B., Barbaroux, C., Brixy, F. (1994) Strong uptake of mIn-pentetreotide by an MIBG-negative, xenografted neuroblastoma. International Journal of Cancer 57: 245–246.CrossRefGoogle ScholarPubMed
Moertel, C. L., Reubi, J. C., Scheithauer, B. S., Schaid, D. J., Kvols, L. K. (1994) Expression of somatostatin receptors in childhood neuroblastoma. American Journal of Clinical Pathology 102: 752–756.CrossRefGoogle ScholarPubMed
O'orisio, M. S., Chen, F., O'Dorisio, T. M., Wray, D., Qualman, S. J. (1994a) Characterization of somatostatin receptors on human neuroblastoma tumours. Cell Growth and Differentiation 5: 1–8.Google Scholar
O'Dorisio, M. S., Hauger, M., Cecalupo, A. J. (1994b) Somatostatin receptors in neuroblastoma: diagnostic and therapeutic implications. Seminars in Oncology 21 (Suppl 13): 33–37.Google ScholarPubMed